– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –
– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –
https://finance.yahoo.com/news/vir-biotechnology-announces-clinical-data-110000962.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.